Milton Ault III Sells 38,324 Shares of Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 38,324 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $2.31, for a total value of $88,528.44. Following the completion of the transaction, the director owned 35,192 shares in the company, valued at approximately $81,293.52. The trade was a 52.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Alzamend Neuro Trading Up 2.9%

ALZN opened at $2.45 on Thursday. Alzamend Neuro, Inc. has a one year low of $2.06 and a one year high of $17.10. The business’s 50-day simple moving average is $2.42 and its 200-day simple moving average is $4.19.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro at the end of the most recent quarter. Institutional investors own 49.61% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on ALZN. Wall Street Zen downgraded Alzamend Neuro from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Ascendiant Capital Markets dropped their price target on Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Alzamend Neuro presently has a consensus rating of “Buy” and an average target price of $42.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.